Roberto Iacovelli
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 263 publications
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.
Journal: The New England journal of medicine
Published: July 01, 2026
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors.
Journal: European urology open science
Published: June 08, 2026
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.
Journal: Tumori
Published: May 04, 2026
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: March 23, 2026
Correction: Schubert et al. Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. Life 2026, 16, 73.
Journal: Life (Basel, Switzerland)
Published: March 05, 2026
Gut microbiome impact on systemic therapy outcomes in metastatic renal cell carcinoma: a systematic review.
Journal: World journal of urology
Published: February 22, 2026
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions.
Journal: Cancers
Published: January 26, 2026
Clinical and technical insights on KIM-1: what we need to know.
Journal: Minerva urology and nephrology
Published: January 19, 2026
Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy.
Journal: Cancer immunology, immunotherapy : CII
Published: January 16, 2026
Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery.
Journal: Life (Basel, Switzerland)
Published: December 05, 2025
Last Updated: 09/26/2026